152 related articles for article (PubMed ID: 7737911)
1. p53 mutations occur in clinical, but not latent, human prostate carcinoma.
Konishi N; Hiasa Y; Hayashi I; Matsuda H; Tsuzuki T; Ming T; Kitahori Y; Shiraishi T; Yatani R; Shimazaki J
Jpn J Cancer Res; 1995 Jan; 86(1):57-63. PubMed ID: 7737911
[TBL] [Abstract][Full Text] [Related]
2. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
3. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
4. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries.
Watanabe M; Ushijima T; Kakiuchi H; Shiraishi T; Yatani R; Shimazaki J; Kotake T; Sugimura T; Nagao M
Jpn J Cancer Res; 1994 Sep; 85(9):904-10. PubMed ID: 7961118
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor gene p53 mutations in human prostate cancer.
Kubota Y; Shuin T; Uemura H; Fujinami K; Miyamoto H; Torigoe S; Dobashi Y; Kitamura H; Iwasaki Y; Danenberg K
Prostate; 1995 Jul; 27(1):18-24. PubMed ID: 7603913
[TBL] [Abstract][Full Text] [Related]
7. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
Incognito LS; Cazares LH; Schellhammer PF; Kuban DA; Van Dyk EO; Moriarty RP; Wright GL; Somers KD
Int J Oncol; 2000 Oct; 17(4):761-9. PubMed ID: 10995889
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
[TBL] [Abstract][Full Text] [Related]
10. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis.
Rakozy C; Grignon DJ; Li Y; Gheiler E; Gururajanna B; Pontes JE; Sakr W; Wood DP; Sarkar FH
Pathol Res Pract; 1999; 195(3):129-35. PubMed ID: 10220791
[TBL] [Abstract][Full Text] [Related]
11. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
Shi XB; Bodner SM; deVere White RW; Gumerlock PH
Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
[TBL] [Abstract][Full Text] [Related]
12. p53 gene alterations in human prostate carcinoma.
Effert PJ; McCoy RH; Walther PJ; Liu ET
J Urol; 1993 Jul; 150(1):257-61. PubMed ID: 8510267
[TBL] [Abstract][Full Text] [Related]
13. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
14. p53 in prostate cancer: frequent expressed transition mutations.
Chi SG; deVere White RW; Meyers FJ; Siders DB; Lee F; Gumerlock PH
J Natl Cancer Inst; 1994 Jun; 86(12):926-33. PubMed ID: 7515114
[TBL] [Abstract][Full Text] [Related]
15. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
16. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.
Effert PJ; Neubauer A; Walther PJ; Liu ET
J Urol; 1992 Mar; 147(3 Pt 2):789-93. PubMed ID: 1347085
[TBL] [Abstract][Full Text] [Related]
18. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
19. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism.
Oyasu R; Nan L; Szumel RC; Kawamata H; Hirohashi S
Mod Pathol; 1995 Feb; 8(2):170-6. PubMed ID: 7777479
[TBL] [Abstract][Full Text] [Related]
20. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.
Konishi N; Hiasa Y; Matsuda H; Tao M; Tsuzuki T; Hayashi I; Kitahori Y; Shiraishi T; Yatani R; Shimazaki J
Am J Pathol; 1995 Oct; 147(4):1112-22. PubMed ID: 7573356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
